Edition:
United Kingdom

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

0.98EUR
19 Oct 2018
Change (% chg)

€0.00 (+0.26%)
Prev Close
€0.98
Open
€1.00
Day's High
€1.00
Day's Low
€0.98
Volume
100,970
Avg. Vol
149,325
52-wk High
€2.49
52-wk Low
€0.98

Latest Key Developments (Source: Significant Developments)

Onxeo H1 Net Loss Eur 8.8 Million
Friday, 27 Jul 2018 

July 27 (Reuters) - Onxeo SA ::* CLINICAL DEVELOPMENT OF ONXEO'S LEAD PRODUCT CANDIDATE ASIDNA PROGRESSING TO PLAN.SAYS PRELIMINARY SAFETY AND ACTIVITY RESULTS OF DRIIV-1 STUDY ARE EXPECTED IN Q4 2018.SAYS TWO COMBINATION CLINICAL TRIALS WITH ASIDNA™ PLANNED FOR EARLY 2019.NEW OPTIMIZED CANDIDATE FROM PLATON PROPRIETARY PLATFORM READY TO ENTER PRECLINICAL STAGE BY END 2018.SAYS CASH POSITION OF EUR 11M AT JUNE 30, 2018 ENABLES AN EXPANDED CLINICAL DEVELOPMENT PLAN OF ASIDNA™ INTO 2020.SAYS NEW OPTIMIZED CANDIDATE FROM PLATON™ PROPRIETARY PLATFORM READY TO ENTER PRECLINICAL STAGE BY END 2018.H1 NET LOSS EUR 8.8 MILLION VERSUS LOSS OF EUR 11.6 MILLION YEAR AGO.H1 OPERATING LOSS EUR 5.5 MILLION VERSUS LOSS OF EUR 11.3 MILLION YEAR AGO.H1 REVENUE EUR 2.1 MILLION VERSUS EUR 3.4 MILLION YEAR AGO.SAYS S PATENTED CHEMISTRY PLATFORM ENABLES COMPANY TO GENERATE ADDITIONAL INNOVATIVE DNA-TARGETING DRUG CANDIDATES..SAYS SEVERAL COMPOUNDS ARE CURRENTLY IN SELECTION AND OPTIMIZATION PHASE AND ONXEO EXPECTS TO INITIATE PRECLINICAL EVALUATION OF A NEW DRUG CANDIDATE BY END OF 2018.  Full Article

Onxeo Publishes A Cash Position Of Eur 9.2 Million At March 31, 2018
Wednesday, 16 May 2018 

May 16 (Reuters) - ONXEO SA ::CASH POSITION OF EUR 9.2 MILLION AT MARCH 31, 2018, SUFFICIENT TO SUPPORT COMPANY'S OPERATIONS UNTIL MID-2019.DEVELOPMENT OF LEAD PRODUCT CANDIDATE, ASIDNA™, FOR THE TREATMENT OF ADVANCED SOLID TUMORS, PROGRESSING ACCORDING TO PLAN.DRIIV PHASE I CLINICAL TRIAL ONGOING.INTERIM RESULTS EXPECTED IN H2 2018.Q1 REVENUES EUR 687,00.  Full Article

Onxeo FY Recurring Operating Loss Narrows To EUR 19.2‍​ Million
Thursday, 29 Mar 2018 

March 29 (Reuters) - ONXEO SA ::FY REVENUE EUR ‍​9.5 MILLION VERSUS EUR 4.4 MILLION YEAR AGO.FY RECURRING OPERATING LOSS EUR 19.2‍​ MILLION VERSUS LOSS OF EUR 23.2 MILLION YEAR AGO.FY NET LOSS EUR 59.1‍​ MILLION VERSUS LOSS OF EUR 22.7 MILLION YEAR AGO.END-DEC. CASH POSITION OF EUR 14.3 MILLION, COVERING CURRENT PROGRAMME UNTIL MID-2019.LAUNCH OF PRECLINICAL STUDIES WITH FIRST MOLECULE GENERATED BY PLATON EXPECTED BEFORE END-2018.RESULTS OF STUDY ON COMBINATION OF BELINOSTAT AND ASIDNA TO BE PRESENTED AT 2018 AACR CONGRESS.RESULTS OF SECOND PHASE I CLINICAL STUDY WITH ASIDNA, DRIIV, EXPECTED BEFORE YEAR-END.SAYS MIGHT BE ABLE TO LAUNCH CLINICAL TRIAL WITH BELINOSTAT AND ASIDNA COMBINATION IN 2018.  Full Article

Onxeo Says To Record Impairment Charge
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Onxeo Sa ::ONXEO SA <<>> SAYS IT WILL RECORD AN IMPAIRMENT CHARGE OF ABOUT EUR 38 MILLION IN ITS 2017 CONSOLIDATED ACCOUNTS.ONXEO SA <<>> - IMPAIRMENT CHARGE PURSUANT TO VALUE TESTS PERFORMED IN ACCORDANCE WITH IFRS ACCOUNTING STANDARDS.ONXEO SA <<>> SAYS ACCOUNTING ADJUSTMENT DOES NOT IMPACT IN ANY WAY CO'S CURRENT OR FUTURE CASH BALANCE.  Full Article

Onxeo gets 10th positive DSMB recommendation to continue Livatag relive phase III trial in HCC
Tuesday, 23 May 2017 

May 23 (Reuters) - ONXEO SA :ONXEO ANNOUNCES 10TH POSITIVE DSMB RECOMMENDATION TO CONTINUE LIVATAG® RELIVE PHASE III TRIAL IN HCC.  Full Article

BRIEF-Onxeo Announces Start Of DRIIV Phase 1 Clinical Study Of AsiDNA

* ANNOUNCES START OF DRIIV, PHASE 1 CLINICAL STUDY OF ASIDNA IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)